

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022)

- By Type- ALD and NAFLD
- ALD Stages - Alcoholic Steatosis and Alcoholic Steatohepatitis
- NAFLD Stages - Non Alcoholic Steatosis and NASH
- By Region- North America, Europe, Asia Pacific and ROW
- By Country - United States, Canada, United Kingdom, Germany, France, India, Japan, China, Saudi Arabia, South Africa, Brazil.



Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)

<input type="checkbox"/> Scope of the Study	<input type="checkbox"/> Global Coverage <input type="checkbox"/> Regional Coverage <input type="checkbox"/> Country Coverage	<input type="checkbox"/> By Type <input type="checkbox"/> By NAFLD Stages <input type="checkbox"/> By ALD Stages <input type="checkbox"/> By Type of Drugs	<input type="checkbox"/> Region (North America, Europe, APAC and ROW) <input type="checkbox"/> Country (U.S., Canada, China, Japan, India , Germany, France, United Kingdom, Saudi Arabia, South Africa, Brazil,)
--	---	---	---

Global Coverage

- Fatty Liver Disease Market – By Value (2012-2022)
- Breakdown-By Type (2012-2021)
 - ALD
 - NAFLD
- Breakdown –By NAFLD Stages (2012-2022): (Steatosis , NASH)
- Breakdown –By ALD Stages (2012-2022): (Steatosis, Alcohol Hepatitis)
- Breakdown by ALD drugs(2012-2022): (Opioid Antagonist ,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor)
- Breakdown By NAFLD Drug(2012-2022) : (Antioxidants Thiazolidinedione, Biguanides, Hypolipidemic Agents, FXR receptor agonist, Elafibranoer)

Regional Coverage

- North America
- Europe
- Asia Pacific
- ROW

- Fatty Liver Disease Market - By Value (2012-2016)
- Fatty Liver Disease Market – By Value (2017-2022)
- Fatty Liver Disease Market – By Type (2012-2022)
- Fatty Liver Disease Market –By ALD Drugs (2012-2022)
- Fatty Liver Disease Market- By NAFLD Drug

Country Coverage

- U.S.
- Canada
- Germany
- France
- U.K.
- China
- Japan
- India
- Brazil
- South Africa
- South Arabia

- Fatty Liver Disease Market : By Value (2012-2022)
- Fatty Liver Disease Market : By Type , By Value (2012-2022)

Company Coverage

- Pfizer
- Conatus
- Novartis
- Intercept pharmaceuticals
- Allergan
- Immuron
- Takeda
- Gilead sciences
- Genfitt

- Product Benchmarking
- Sales
- Business Overview
- Product Launches & Recent Approvals
- Merger & Acquisition

Table of Content

S. No	Particulars	Page No.
1.	Research Methodology	22
2.	Executive Summary	23
3.	Strategic Recommendation	24
3.1	Focus on Asia Region	25
3.2	Focus on drug development for NASH and Alcohol Hepatitis	26
3.3	Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis	27
4.	Fatty Liver Market Outlook	28
5.	Global Fatty Liver Disease Market: Growth and Forecast	36
5.1	By Value (2012-2016)	37
5.2	By Value (2017-2022)	38
6	Global Fatty Liver Disease –By Type	39
6.1	Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver Disease (NAFLD)): Breakdown(%)	39
6.1.1	Global Fatty Liver Disease Market-By Type,2016 (%)	40
6.1.2	Global Fatty Liver Disease Market-By Type,2022 (%)	41
6.2	Global Fatty Liver Disease –By Type, By Value	42
6.2.1	Global Alcoholic Fatty Liver Disease Market	42
6.2.1.1	By Value (2012-2022)	42

Table of Content

S. No	Particulars	Page No.
	6.2.2 Global Non Alcoholic Fatty Liver Disease Market	44
	6.2.2.1 By Value (2012-2022)	44
7.	Global Alcoholic Fatty Liver Disease Market –By Stages	47
7.1	Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis): Breakdown(%)	47
7.1.1	Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)	48
7.1.2	Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)	49
7.2	Global Alcoholic Fatty Liver Disease Market -By Stages, By Value	50
7.2.1	Global Alcoholic Steatosis Market	50
	7.2.1.1 By Value (2012-2022)	50
7.2.2	Global Alcoholic Steatohepatitis Market	52
	7.2.2.1 By Value (2012-2022)	52
8.	Global Non Alcoholic Fatty Liver Disease Market–By Stages	54
8.1	Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic Steatohepatitis) : Breakdown(%)	54
8.1.1	Global Non Alcoholic Fatty Liver Disease Market -By Stages , 2016(%)	55
8.2.1	Global Non Alcoholic Fatty Liver Disease Market -By Stages , 2022 (%)	56

Table of Content

S. No	Particulars	Page No.
8.2	Global Non Alcoholic Fatty Liver Disease Market -By Stages , By Value	57
8.2.1	Global Non Alcoholic Steatosis Market	57
8.2.1.1	By Value (2012-2022)	57
8.2.2	Global Non Alcoholic Steatohepatitis Market	58
8.2.2.1	By Value (2012-2022)	58
9.	Global Alcoholic Fatty Liver Disease Market –By Drugs	61
9.1	Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoide Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) : Breakdown(%)	61
9.1.1	Global Alcoholic Fatty Liver Disease Market -By Drugs , 2016(%)	62
9.1.2	Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2022 (%)	63
9.2	Global Alcoholic Fatty Liver Disease Market -By Drugs , By Value	64
9.2.1	Global Opioid Antagonist Drug Market	64
	By Value (2012-2022)	64
9.2.2	Global Pentoxifylline Drug Market	66
	By Value (2012-2022)	66
9.2.3	Global Glucocorticoid Drug Market	67
	By Value (2012-2022)	67

Table of Content

S. No	Particulars	Page No.
9.2.4	Global Antioxidants Drug market	69
9.2.4.1	By Value (2012-2022)	69
9.2.5	Global Granulocyte colony stimulating factor Drug Market	71
9.2.5.1	By Value (2012-2022)	71
10.	Global Non Alcoholic Fatty Liver Disease Market –By Drugs	73
10.1	Global Non Alcoholic Fatty Liver Disease Market -By Drugs (Antioxidants, Thiazolidinedione, Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor) : Breakdown(%)	73
10.1.1	Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2016(%)	74
10.2.1	Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2022 (%)	75
10.2	Global Non Alcoholic Fatty Liver Disease Market -By Drugs , By Value	76
10.2.1	Global Antioxidants Drug Market	76
10.2.1.1	By Value (2012-2022)	76
10.2.2	Global Thiazolidinedione Drug Market	78
10.2.2.1	By Value (2012-2022)	78
10.2.3	Global Biguanides Drug Market	80
10.2.3.1	By Value (2012-2022)	80

Table of Content

S. No	Particulars	Page No.
10.2.4	Global Hypolipidemic Agents Drug market	82
	10.2.4.1 By Value (2012-2022)	82
10.2.5	Global FXR Receptor Agonist Drug Market	84
	10.2.5.1 By Value (2012-2022)	84
10.2.6	Global Elafibranor Drug Market	86
	10.2.6.1 By Value (2012-2022)	86
11.	Global Fatty Liver Disease Market – Pipeline Analysis (By developer, Phase and indication)	88
12.	Global Fatty Liver Disease Market – Regional Analysis	93
12.1	Global Fatty Liver Disease Market -By Regional : Breakdown(%)	93
	12.1.1 Global Fatty Liver Disease Market -By Region, 2016(%)	94
	12.1.2 Global Fatty Liver Disease Market -By Region, 2022 (%)	95
13.	North America Fatty liver Disease Market	96
13.1	By Value (2012-2022)	97
13.2	North America Fatty liver Disease Market – By Type , By Value	100
13.3	North America Fatty liver Disease Market – By ALD Drug , By Value	102

Table of Content

S. No	Particulars	Page No.
13.4	North America Fatty liver Disease Market – By NAFLD Drug , By Value	104
14.	North America Fatty Liver Disease Market –By Country Analysis	105
14.1	North America Fatty Liver Disease Market –By Country ,2012-2016(%)	106
14.2	North America Fatty Liver Disease Market –By Country ,2017E-2022F(%)	106
14.3	United States Fatty Liver Disease Market – By Value(2012-2022)	107
14.3.1	United States Fatty Liver Disease Market By Type, By Value	109
14.4	Canada Fatty Liver Disease Market – By Value(2012-2022)	110
14.4.1	Canada Fatty Liver Disease Market By Type, By Value	111
15.	Asia Pacific Fatty liver Disease Market	113
15.1	By Value (2012-2022)	114
15.2	Asia Pacific Fatty liver Disease Market – By Type , By Value	117
15.3	Asia Pacific Fatty liver Disease Market – By ALD Drug , By Value	119
15.4	Asia Pacific Fatty liver Disease Market – By NAFLD Drug , By Value	121
16.	Asia Pacific Fatty Liver Disease Market –By Country Analysis	122
16.1	Asia Pacific Fatty Liver Disease Market –By Country ,2012-2016(%)	123
16.2	Asia Pacific Fatty Liver Disease Market –By Country ,2017E-2022F(%)	123

Table of Content

S. No	Particulars	Page No.
16.3	India Fatty Liver Disease Market – By Value(2012-2022)	124
16.3.1	India Fatty Liver Disease Market By Type, By Value	126
16.4	China Fatty Liver Disease Market – By Value(2012-2022)	127
16.5	Japan Fatty Liver Disease Market – By Value(2012-2022)	129
16.5.1	Japan Fatty Liver Disease Market By Type, By Value	130
16.6	Rest of Asia Fatty Liver Disease Market-By Value(2012-2022)	131
17.	Europe Pacific Fatty liver Disease Market	132
17.1	By Value (2012-2022)	133
17.2	Europe Fatty liver Disease Market – By Type , By Value	137
17.3	Europe Fatty liver Disease Market – By ALD Drug , By Value	139
17.4	Europe Fatty liver Disease Market – By NAFLD Drug , By Value	141
18.	Europe Fatty Liver Disease Market –By Country Analysis	142
18.1	Europe Fatty Liver Disease Market –By Country ,2012-2016(%)	143
18.2	Europe Fatty Liver Disease Market –By Country ,2017E-2022F(%)	143

Table of Content

S. No	Particulars	Page No.
18.3	United Kingdom Fatty Liver Disease Market – By Value(2012-2022)	144
18.3.1	United Kingdom Fatty Liver Disease Market By Type, By Value	145
18.4	Germany Fatty Liver Disease Market – By Value(2012-2022)	147
18.4.1	Germany Fatty Liver Disease Market By Type, By Value	149
18.5	France Fatty Liver Disease Market – By Value(2012-2022)	150
18.5.1	France Fatty Liver Disease Market By Type, By Value	151
18.6	Rest of Europe Fatty Liver Disease Market-By Value(2012-2022)	152
19.	Rest of World Fatty liver Disease Market	153
19.1	By Value (2012-2022)	154
19.2	Rest of World Fatty liver Disease Market – By Type , By Value	156
19.3	Rest of World Fatty liver Disease Market – By ALD Drug , By Value	158
19.4	Rest of World Fatty liver Disease Market – By NAFLD Drug , By Value	160
20.	Rest of World Fatty Liver Disease Market –By Country Analysis	161
20.1	Rest of World Fatty Liver Disease Market –By Country ,2012-2016(%)	162
20.2	Rest of World Fatty Liver Disease Market –By Country ,2017E-2022F(%)	162

Table of Content

S. No	Particulars	Page No.
20.3	Saudi Arabia Fatty Liver Disease Market – By Value(2012-2022)	163
20.3.1	Saudi Arabia Fatty Liver Disease Market By Type, By Value	164
20.4	South Africa Fatty Liver Disease Market – By Value(2012-2022)	166
20.4.1	South Africa Fatty Liver Disease Market By Type, By Value	168
20.5	Brazil Fatty Liver Disease Market – By Value(2012-2022)	169
20.5.1	Brazil Fatty Liver Disease Market By Type, By Value	170
20.6	Others Fatty Liver Disease Market-By Value(2012-2022)	171
21.	Market Dynamics	172
21.1	Drivers	173
21.2	Challenges	177
22.	Market Trends	180
23.	Policy and Regulations	182
24.	Porter Five Force	190
25.	SWOT Analysis	192
26.	Company Profiling	194

Table of Content

S. No	Particulars	Page No.
26.1	Pfizer	195
26.2	Conatus Pharmaceuticals	197
26.3	Novartis	198
26.4	Intercept Pharmaceuticals	200
26.5	Allergan	201
26.6	Immuron	202
26.7	Takeda	203
26.8	Gilead Sciences	205
26.9	Genfit	207
27.	About Us	208

List of Figures

Figure No.	Figure Title	Page No.
Figure 1:	History of Fatty Liver Disease	31
Figure 2:	Therapeutic Algorithm for Management of Alcoholic Hepatitis	32
Figure 3:	Treatment Algorithm of NAFLD	35
Figure 4:	Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million)	37
Figure 5:	Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)	38
Figure 6:	Global Fatty Liver Disease Market Size, By Type, 2016 (%)	40
Figure 7:	Global Fatty Liver Disease Market Size, By Type, 2022F (%)	41
Figure 8:	Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion)	42
Figure 9:	Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion)	42
Figure 10:	Beer Consumption , Billion Liters , 2014	43
Figure 11:	Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion)	44
Figure 12:	Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)	44
Figure 13:	Global Diabetic Population, By Region, 2015 (Million)	46
Figure 14:	Global Alcoholic Liver Disease Market Size, By Stage , 2016 (%)	48
Figure 15:	Global Alcoholic liver Disease Market Size, By Type, 2022F (%)	49
Figure 16:	Global Alcoholic Steatosis Treatment , By Value, 2012-2016 (USD Billion)	50
Figure 17:	Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion)	50
Figure 18:	World Alcohol Consumption , Liters per Capita, 2014-2016	51
Figure 19:	Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion)	52

List of Figures

Figure No.	Figure Title	Page No.
Figure 20:	Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion)	52
Figure 21:	Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)	55
Figure 22:	Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%)	56
Figure 23:	Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion)	57
Figure 24:	Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F(USD Billion)	57
Figure 25:	Global NASH Market, By Value, 2012-2016 (USD Billion)	58
Figure 26:	Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion)	58
Figure 27:	Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)	62
Figure 28:	Global In-flight Catering Service Market Size, By Airline Type, 2022F (%)	63
Figure 29:	Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion)	64
Figure 30:	Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)	64
Figure 31:	Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion)	66
Figure 32:	Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)	66
Figure 33:	Global Glucocorticoid Drug Market, By Value, 2012-2016 (USD Billion)	67
Figure 34:	Global Glucocorticoid Drug Market, By Value Forecast, 2017E-2022F(USD Billion)	67
Figure 35:	Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)\	69
Figure 36:	Global Antioxidants Drug Market, By Value, , Forecast, 2017E-2022F(USD Billion)	69
Figure 37:	Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion)	71
Figure 38:	Global Granulocyte Colony Stimulating Factor Drug Market , By Value, Forecast, 2017E-2022F(USD Billion)	71
Figure 39:	Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)	74

List of Figures

Figure No.	Figure Title	Page No.
Figure 40:	Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%)	75
Figure 41:	Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)	76
Figure 42:	Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion)	76
Figure 43:	Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion)	78
Figure 44:	Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)	78
Figure 45:	Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion)	80
Figure 46:	Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)	80
Figure 47:	Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion)	82
Figure 48:	Global Hypolipidemic Drug Market , By Value, Forecast, 2017E-2022F(USD Billion)	82
Figure 49:	Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion)	84
Figure 50:	Global FXR Receptor Agonist Drug Market , By Value, Forecast, 2017E-2022F (USD Billion)	84
Figure 51:	Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion)	86
Figure 52:	Global Elafibranor Drug Market , By Value, Forecast, 2017E-2022F (USD Billion)	86
Figure 53:	Global Fatty Liver Disease Market Size and Share, By Region, 2016	94
Figure 54:	Global Fatty Liver Disease Market Size and Share, By Segments, 2022F	95
Figure 55:	North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	97
Figure 56:	North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	97
Figure 57:	North America Healthcare Expenditure, 2011-2014 (% of GDP)	98
Figure 58:	North America Population Age 15-64 2015 (% of Total)	98
Figure 59:	North America Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	100
Figure 60:	North America Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)	102

List of Figures

Figure No.	Figure Title	Page No.
Figure 61:	North America Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)	104
Figure 62:	North America Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)	106
Figure 63:	North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)	106
Figure 64:	United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	107
Figure 65:	United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	107
Figure 66:	Percentage of United states adults who had at least one heavy drinking day,2011-2015	108
Figure 67:	United States Alcohol Liters Per Capita Consumption, 2011-2015	108
Figure 68:	United States Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	109
Figure 69:	CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	110
Figure 70:	Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	110
Figure 71:	Canada Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	111
Figure 72:	Canada Alcohol Liters Per Capita Consumption, 2011-2015	112
Figure 73:	Prevalence of Obese and overweight Population , By Age,2014(%)	112
Figure 74:	Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	114
Figure 75:	Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	114
Figure 76:	Obesity Prevalence in Asian Countries, 2014 (%)	115
Figure 77:	Asia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	117
Figure 78:	Asia Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)	119
Figure 79:	Asia Pacific Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)	121
Figure 80:	Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)	123

List of Figures

Figure No.	Figure Title	Page No.
Figure 81:	Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)	123
Figure 82:	India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	124
Figure 83:	India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	124
Figure 84:	Percentage of United states adults who had at least one heavy drinking day, 2011-2015	125
Figure 85:	India Alcohol Liter per capita Consumptions, 2015-2016	125
Figure 86:	India Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	126
Figure 87:	China Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	127
Figure 88:	China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	127
Figure 89:	Health expenditure in China,2011-2015 (USD Billion)	128
Figure 90:	China Alcohol Liter per capita Consumptions,2015-2016	128
Figure 91:	Japan Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	129
Figure 92:	Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	129
Figure 93:	Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	130
Figure 94:	Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	131
Figure 95:	Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	131
Figure 96:	Europe Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	133
Figure 97:	Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	133
Figure 98:	Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79)	134
Figure 99:	EU Health Expenditure Per Capita, 2011-2014 (USD)	135
Figure 100:	Breakdown of Total Health Expenditure in Europe (%)	135

List of Figures

Figure No.	Figure Title	Page No.
Figure 101:	Europe Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	137
Figure 102:	Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)	139
Figure 103:	Europe Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)	141
Figure 104:	Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)	143
Figure 105:	Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)	143
Figure 106:	United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	144
Figure 107:	United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	144
Figure 108:	United Kingdom Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	145
Figure 109:	Alcohol Related Disease Death, 2015	146
Figure 110:	Diabetes Prevalence in U.K. 2015	146
Figure 111:	Five Day Drinking Prevalence By Age, (%), 2014-2015	146
Figure 112:	Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	147
Figure 113:	Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	147
Figure 114:	Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015	148
Figure 115:	Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F.	148
Figure 116:	Alcohol Consumption per capita ,2012-2016 (liter) in Germany	148
Figure 117:	Germany Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million)	149
Figure 118:	France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	150
Figure 119:	France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	150
Figure 120:	France Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million)	151

List of Figures

Figure No.	Figure Title	Page No.
Figure 121:	Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	152
Figure 122:	Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	152
Figure 123:	Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	154
Figure 124:	Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	154
Figure 125:	Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	156
Figure 126:	Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	158
Figure 127:	Rest of world Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)	160
Figure 128:	Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)	162
Figure 129:	Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)	162
Figure 130:	Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	163
Figure 131:	Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	163
Figure 132:	Saudi Arabia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	164
Figure 133:	Saudi Arabia Prevalence of Obesity Forecast 2022 (%)	165
Figure 134:	South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	166
Figure 135:	South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	166
Figure 136:	South Africa Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	168
Figure 137:	Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)	169
Figure 138:	Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	169
Figure 139:	Brazil Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)	170
Figure 140:	Others Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)	171

List of Figures

Figure No.	Figure Title	Page No.
Figure 141:	Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)	171
Figure 142:	Pfizer Segmental Breakup, 2016(%)	196
Figure 143:	Pfizer Sales, By Region, 2016 (%)	196
Figure 144:	Novartis Sales, By Segment 2015 (%)	199
Figure 145:	Novartis Sales, By Region,2015 (%)	199
Figure 146:	Novartis Pharmaceuticals Sales, By Franchise, 2015 (%)	199
Figure 147:	Takeda Segmental Breakup	204
Figure 148:	Takeda Revenue, 2013-2016 (USD Million)	204
Figure 149:	Gilead Sciences Product Sales, 2016 (%)	206
Figure 150:	Gilead Sciences HCV Product Sales, 2014-2016 (USD Billion)	206

List of Tables

Table No.	Table Title	Page No.
Table A:	Causes of NAFLD Infection	33
Table B:	Quantity of Alcohol in Standard Drink	51
Table C:	Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication	89
Table D:	Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication	90
Table E:	Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication	91
Table F:	NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status	92

Research Definition

Global Fatty Liver Disease Treatment Market Report comprises of the study of various aspects of Fatty Liver Market and forecast until 2022. Global Fatty Liver Disease Treatment Market has been segmented on basis of Types (Alcoholic and Non Alcoholic Fatty Liver); Alcoholic Fatty Liver By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis), Non Alcoholic Fatty Liver Stages By Stages (Alcoholic Steatosis and Non Alcoholic Steatohepatitis), By Region (North America, Europe, APAC, Middle East and ROW) and By Country (U.S., Canada, Germany, Russia, United Kingdom, China, India, Japan, Brazil, Mexico, Saudi Arabia, South Africa and UAE)

Data Analysis and Interpretation

Our historic market trend has been figured out by various paid databases which was further triangulated with inputs and insights from industry experts, companies and stakeholders, through primary research (manufacturers, marketing managers, others). Back-of-the-Envelope calculation for the market estimation has been made through proper understanding of the market as well as future business strategies of the companies operating in the market. The Report has covered only two stages drug treatment for Alcoholic and Non alcoholic fatty liver.


Azoth Analytics has conducted quantitative as well as qualitative research to gather market insights such as market sizing, market segmentation, recent trends and developments and competitive landscape. Our team has conducted extensive primary surveys by reaching out industry experts across the value chain of the global orthopaedic market.

Companies Contacted: St Stephen Hospital Delhi

Global Fatty Liver Disease Market Overview

Global Fatty liver Disease market in the forecasted period will witness rapid growth owing to several NASH Drug expected to enter the market in forecasted period.

Figure : Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)




Source: Azoth Analytics Estimates

- A XXXX
- A XXXX
- A XXXX
- A XXXX
- A XXXX
- A XXXX


Global Non Alcoholic Liver Disease Market-By Stages

NASH treatment held the majority market share of approximately 81.67%, by value, in the year 2016.

Figure : Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)



Key Drivers



Source: Azoth Analytics Estimates


North America Fatty Liver Disease Market

Figure : North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

Figure : North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

CAGR 2012-2015
xxxx%

CAGR 2016-2022
xxxx%



Source: Azoth Analytics Estimates

- A XXXX
- A XXXX
- A XXXX
- A XXXX
- A XXXX

Japan Fatty Liver Disease Market, By Type


Figure 93: Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

CAGR 2012-2016

Alcoholic Fatty Liver Disease: xxxx%
 Non Alcoholic Fatty Liver Disease : xxxx%

CAGR 2017-2022

Alcoholic Fatty Liver Disease: xxxx%
 Non Alcoholic Fatty Liver Disease : xxxx%



Source: Azoth Analytics Estimates


- A) Xxxxx
- A) Xxxxx
- A) Xxxxx
- A) xxxxx

Europe Fatty Liver Disease Market, By NAFALD Drug

Figure : Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)

CAGR 2012-201
 Antioxidants: xxxx%
 Thiazolidinedione: xxxx%
 Biguanidies: xxxx%
 HypolipidemicAgents: xxxx%
 FXR Receptor Agonist: xxxx%
 Elafibranor: xxxx %

CAGR 2017-2022
 Antioxidants: xxxx%
 Thiazolidinedione: xxxx%
 Biguanidies: xxxx%
 Hypolipidemic agents: xxxxx%
 FXR Receptor Agonist: xxxxx%
 Elafibranor: xxxx%



Source: Azoth Analytics Estimates

- A XXXX
- A XXXX
- A XXXX

About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

Related Reports:

Global Vitreoretinal Surgery Devices Market (By Product, By End User, By Region, By Country): Opportunities and Forecast (2016-2021)

– By Product (Vitreotomy Machines & Packs, Photocoagulation Surgery Devices, Illumination Devices, Others); By End User (Hospitals, Free Standing Ambulatory Surgery Center); By Region (North America, Europe, APAC, ROW); By Country (US, Canada, Mexico, UK, Germany, France, Japan, China, India, Brazil, South Africa)

Global Biomaterials Market (By Type, By Application, By Region): Opportunities and Forecasts (2016-2021) - (By Material Type – Polymer, Ceramic, Metal; By Application - Orthopaedic, Cardiovascular, Plastic Surgery, Wound Care); By Region-North America, Europe, APAC, ROW; By Country –

US, UK, Germany, Italy, Japan, China, India; Key Players – Strategy, Financial Performance)

Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers' internal use only and not for general publication or disclosure to third parties.